M&T Bank Corp Has $12.80 Million Stake in Becton, Dickinson and Company (NYSE:BDX)

M&T Bank Corp boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 1.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 53,102 shares of the medical instruments supplier’s stock after buying an additional 996 shares during the quarter. M&T Bank Corp’s holdings in Becton, Dickinson and Company were worth $12,803,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its holdings in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after acquiring an additional 1,317,723 shares during the period. First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock worth $655,149,000 after purchasing an additional 688,296 shares during the period. Massachusetts Financial Services Co. MA lifted its stake in Becton, Dickinson and Company by 9.4% in the third quarter. Massachusetts Financial Services Co. MA now owns 5,365,554 shares of the medical instruments supplier’s stock valued at $1,293,635,000 after buying an additional 460,440 shares during the period. Vaughan Nelson Investment Management L.P. bought a new position in Becton, Dickinson and Company during the third quarter worth about $108,243,000. Finally, The Manufacturers Life Insurance Company grew its position in shares of Becton, Dickinson and Company by 62.2% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 1,107,317 shares of the medical instruments supplier’s stock worth $266,974,000 after buying an additional 424,487 shares during the period. 86.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Michael David Garrison sold 2,838 shares of the stock in a transaction that occurred on Thursday, December 19th. The stock was sold at an average price of $223.33, for a total transaction of $633,810.54. Following the sale, the executive vice president now owns 6,141 shares of the company’s stock, valued at $1,371,469.53. This represents a 31.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Roland Goette sold 638 shares of Becton, Dickinson and Company stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total value of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 7,959 shares of company stock worth $1,764,340 over the last three months. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.7 %

Becton, Dickinson and Company stock opened at $227.68 on Friday. The stock has a 50-day simple moving average of $229.88 and a 200 day simple moving average of $233.16. The stock has a market capitalization of $65.83 billion, a P/E ratio of 38.33, a PEG ratio of 1.64 and a beta of 0.41. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.74 and a current ratio of 1.17. Becton, Dickinson and Company has a 52 week low of $218.75 and a 52 week high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the firm earned $3.42 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. Analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be issued a $1.04 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a yield of 1.83%. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on BDX shares. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $283.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.